Back to Journals » Drug Design, Development and Therapy » Volume 2

Raltegravir in the management of HIV-infected patients

Authors Stellbrink H

Published 23 December 2008 Volume 2008:2 Pages 281—288

DOI https://doi.org/10.2147/DDDT.S3337

Review by Single anonymous peer review

Peer reviewer comments 2


Hans-Jürgen Stellbrink

ICH and IPM Study Center Hamburg, Hamburg, Germany

Abstract: Raltegravir has recently been licensed for the treatment of HIV-1 infection. Currently its use is limited to treatment-experienced patients and subjects with resistant virus. In addition to its activity in the setting of resistance and treatment failure, it appears to have great potential for first-line therapy and as a switch option for subjects with intolerance to other agents, as well. Overall tolerability in clinical trials was excellent, and the toxicity profile is non-overlapping with other agents, with no clear neuropsychiatric, gastrointestinal, or metabolic toxicity. Its metabolization occurs mainly via UGT1A1 rather than by the CYP450 system, resulting in a relatively unproblematic drug interaction profile. The independence of the compound from “boosting” of drug levels with ritonavir is an attractive feature for many patients suffering from ritonavir-associated side effects. However, it has to be dosed twice daily. The unique effect of raltegravir on the establishment of viral latency makes it a logical component of treatment attempts aiming at reducing and controlling this viral sanctuary. This review summarizes the clinical view on the role of this novel compound in HIV therapy.

Keywords: raltegravir, MK-0518, integrase inhibitor, HIV infection, HAART

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]